2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase
  5. NO Synthase Isoform
  6. NO Synthase Antagonist

NO Synthase Antagonist

NO Synthase Antagonists (3):

Cat. No. Product Name Effect Purity
  • HY-141411B
    (R)-Zevaquenabant
    		Antagonist 99.15%
    (R)-Zevaquenabant ((R)-MRI-1867) is the enantiomer of Zevaquenabant (HY-141411A). Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).
  • HY-18732B
    L-NMMA citrate
    		Antagonist
    L-NMMA (Tilarginine) citrate is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA citrate inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production. L-NMMA citrate alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA citrate is applicable to research related to nociception, bone cancer pain, and myopia.
  • HY-18732C
    L-NMMA hydrochloride
    		Antagonist
    L-NMMA (Tilarginine) hydrochloride is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA hydrochloride inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production. L-NMMA hydrochloride alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA hydrochloride is applicable to research related to nociception, bone cancer pain, and myopia.